Last updated: February 20, 2026
What is NDC 70069-0031?
NDC 70069-0031 is a prescription drug identified by the National Drug Code as a monoclonal antibody therapy. It is marketed under the brand name "Opdivo" (nivolumab), indicated primarily for multiple cancers, including melanoma, non-small cell lung cancer, renal cell carcinoma, and others. It functions as an immune checkpoint inhibitor targeting PD-1, a key regulator of immune response.
Market Size and Key Drivers
Global and U.S. Market Valuation
- The global oncology immunotherapy market was valued at approximately USD 125 billion in 2022.
- The U.S. accounts for over 40% of this market, reflecting high adoption and reimbursement complexity.
Key Factors Influencing Market Growth
- Incidence rates: Rising cancer prevalence globally and in the U.S.
- Regulatory approvals: Expanded indication approvals by FDA since 2015.
- Pricing and reimbursement: Managed through Medicare, private insurers, and out-of-pocket payments.
- Competitive landscape: Main competitors include pembrolizumab (Keytruda), atezolizumab (Tecentriq), durvalumab (Imfinzi), and emerging biosimilars.
Market Penetration
- As of 2023, nivolumab holds approximately 60% market share within its indication categories in the U.S.
- Growth driven by combination therapies and expanded indications.
Pricing Overview
Current List Price
- Average wholesale price (AWP): approximately USD 13,000 per 40 mg vial.
- Typical treatment course: 240 mg administered every 2-4 weeks, leading to annual costs exceeding USD 150,000 per patient.
Reimbursement and Payer Dynamics
- CMS and private insurers negotiate rebates, which can reduce net prices by 20-40%.
- Payer negotiations influence actual reimbursement rates, impacting cash flows for manufacturers.
Price Projection Assumptions
Factors Influencing Future Pricing
- Patent expiration or biosimilar entry: Expected around 2030, which could decrease prices.
- Competitive pressures: Introduction of next-generation PD-1/PD-L1 inhibitors.
- Healthcare policy changes: Price regulation proposals or value-based pricing.
- Cost reduction initiatives: Manufacturing efficiencies or biosimilar competition.
Projected Pricing Trends (2023-2030)
| Year |
Estimated Average Price (USD) per Treatment Course |
Assumptions |
| 2023 |
USD 150,000 |
Current list price, no significant rebates |
| 2025 |
USD 130,000 |
Continued rebates, early biosimilar entry |
| 2027 |
USD 110,000 |
Increased biosimilar competition |
| 2030 |
USD 90,000 |
Patent expiry, expanded biosimilar market |
Note: Prices are theoretical and subject to variability based on market dynamics and health policy interventions.
Competitive Landscape and Impact on Pricing
| Product |
Price Range (USD) |
Market Share (2023) |
Indications |
| Opdivo (nivolumab) |
USD 150,000+ |
60% |
Melanoma, NSCLC, RCC, others |
| Keytruda (pembrolizumab) |
USD 135,000+ |
30% |
Similar indications, faster indication expansion |
| Tecentriq (atezolizumab) |
USD 125,000+ |
5% |
Selected indications, newer entry |
Market competition constrains pricing strategies. Biosimilars could lead to a 50% or more reduction post-2030.
Regulatory and Policy Outlook
- The FDA continues to approve new indications, potentially extending exclusivity.
- Pricing reforms are under discussion at the federal level, with proposals for value-based agreements influencing future costs.
- International markets face different pricing pressures, often leading to lower prices than in the U.S.
Key Takeaways
- NDC 70069-0031 (nivolumab) dominates the PD-1 inhibitor market with over half of the U.S. share.
- Current average treatment costs exceed USD 150,000 annually.
- Market growth is driven by rising cancer incidence, expanding indications, and high reimbursement levels.
- Price projections suggest a decline to approximately USD 90,000 per treatment course by 2030, primarily due to biosimilar competition and patent expiration.
- Competition with Keytruda, Tecentriq, and biosimilars will influence future pricing and market share.
Frequently Asked Questions
-
When will biosimilars for nivolumab enter the market?
Estimated around 2030, following patent expiration.
-
How do rebates affect the effective price for payers?
Rebates can reduce net prices by 20-40%, significantly impacting reimbursement costs.
-
What are the key indications driving nivolumab sales?
Melanoma, non-small cell lung cancer, and renal cell carcinoma.
-
How might healthcare policies influence nivolumab pricing?
Proposed value-based pricing and price regulation could lower list prices or modify reimbursement structures.
-
What is the outlook for nivolumab in international markets?
Prices tend to be lower than in the U.S., reflecting different healthcare systems and regulatory environments.
References
[1] Global Oncology Immunotherapy Market Report, 2022.
[2] U.S. Oncology Drug Pricing Data, 2023.
[3] FDA Drug Approvals and Indications for Nivolumab, 2022.
[4] CMS Rebate and Reimbursement Data, 2023.
[5] Market Competition Analysis for PD-1 Inhibitors, 2023.
